The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

DENVER — The use of several common antibiotics led to exacerbation of myasthenia gravis in a small cohort of patients, Sanem P. Uysal, MD, said in this Healio video from the American Academy of ...

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

The landscape of gMG treatment is rapidly evolving, said John Morren, MD, of the Cleveland Clinic. The traditional approach to managing gMG involves broad immunosuppressive therapies, but emerging ...

"Delveinsight Business Research LLP"As per DelveInsight's assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Generalized Myasthenia Gravis ...

“Myasthenia Gravis Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Myasthenia Gravis ...

AstraZeneca has bagged a win for its rare disease pipeline, with its Phase III trial of gefurulimab demonstrating the drug’s ...

Nipocalimab (Imaavy; Johnson & Johnson) was approved by the FDA on April 30, 2025, to treat generalized myasthenia gravis in adult patients and pediatric patients 12 years or older who are anti ...

Myasthenia gravis, or MG, is a chronic autoimmune neuromuscular disorder that causes muscle weakness and fatigue. ... it's often treated by administering one of five FDA-approved medications.

The chief executive of Muscular Dystrophy UK and interim chief executive of Myaware UK have shared thoughts on the rejection by the NHS in ...